Post-Marketing Safety Study on Olumiant (Baricitinib) Use Among Moderate to Severe Active Rheumatoid Arthritis Patients in China

23/03/2020
12/11/2024
EU PAS number:
EUPAS34213
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

Non_interventional PASS Protocol_B021(a)

English (400.3 KB - PDF) View document
Updated protocol

Non_interventional PASS Protocol_B021_amendment (b)

First published: 22/02/2024
English (6.13 MB - PDF) View document
Study results
Study results

I4V-GH-B021(b) Non-interventional PASS final study report (3)

English (9.95 MB - PDF) View document
Study report
Other information